IL184803A - Purified antibodies against epha2, methods for their production, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating cancer - Google Patents
Purified antibodies against epha2, methods for their production, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating cancerInfo
- Publication number
- IL184803A IL184803A IL184803A IL18480307A IL184803A IL 184803 A IL184803 A IL 184803A IL 184803 A IL184803 A IL 184803A IL 18480307 A IL18480307 A IL 18480307A IL 184803 A IL184803 A IL 184803A
- Authority
- IL
- Israel
- Prior art keywords
- antigen
- binding fragment
- immunoglobulin
- epha2
- pta
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims abstract description 22
- 201000011510 cancer Diseases 0.000 title claims description 38
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 17
- 239000003814 drug Substances 0.000 title claims description 13
- 238000004519 manufacturing process Methods 0.000 title claims 4
- 239000000427 antigen Substances 0.000 claims abstract description 49
- 102000036639 antigens Human genes 0.000 claims abstract description 49
- 108091007433 antigens Proteins 0.000 claims abstract description 49
- 102000051096 EphA2 Receptor Human genes 0.000 claims abstract description 47
- 108010055196 EphA2 Receptor Proteins 0.000 claims abstract description 47
- 108060003951 Immunoglobulin Proteins 0.000 claims description 52
- 102000018358 immunoglobulin Human genes 0.000 claims description 52
- 239000012634 fragment Substances 0.000 claims description 48
- 210000004027 cell Anatomy 0.000 claims description 40
- 150000007523 nucleic acids Chemical group 0.000 claims 24
- 210000004408 hybridoma Anatomy 0.000 claims 21
- 108020004707 nucleic acids Proteins 0.000 claims 21
- 102000039446 nucleic acids Human genes 0.000 claims 21
- 101150042817 NFS1 gene Proteins 0.000 claims 14
- 101100126298 Rickettsia conorii (strain ATCC VR-613 / Malish 7) iscS gene Proteins 0.000 claims 14
- 101150114492 SPL1 gene Proteins 0.000 claims 14
- 239000003550 marker Substances 0.000 claims 10
- 229940124597 therapeutic agent Drugs 0.000 claims 10
- 238000000338 in vitro Methods 0.000 claims 6
- 238000001727 in vivo Methods 0.000 claims 6
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 claims 6
- 230000035755 proliferation Effects 0.000 claims 6
- 210000004881 tumor cell Anatomy 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 238000003306 harvesting Methods 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 101000962530 Homo sapiens Hyaluronidase-1 Proteins 0.000 claims 1
- 102100039283 Hyaluronidase-1 Human genes 0.000 claims 1
- 241000539428 Hybroma Species 0.000 claims 1
- 210000000481 breast Anatomy 0.000 abstract description 4
- 238000012512 characterization method Methods 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 101150076616 EPHA2 gene Proteins 0.000 description 6
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940127121 immunoconjugate Drugs 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000004565 tumor cell growth Effects 0.000 description 3
- 241000557626 Corvus corax Species 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Nanotechnology (AREA)
- Toxicology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65004705P | 2005-02-04 | 2005-02-04 | |
| PCT/US2006/004057 WO2006084226A2 (en) | 2005-02-04 | 2006-02-06 | Antibodies that bind to epha2 and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL184803A0 IL184803A0 (en) | 2007-12-03 |
| IL184803A true IL184803A (en) | 2011-04-28 |
Family
ID=36778009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL184803A IL184803A (en) | 2005-02-04 | 2007-07-24 | Purified antibodies against epha2, methods for their production, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7569672B2 (enExample) |
| EP (1) | EP1846450B1 (enExample) |
| JP (1) | JP5342145B2 (enExample) |
| KR (1) | KR101363252B1 (enExample) |
| CN (2) | CN104059150B (enExample) |
| AT (1) | ATE551367T1 (enExample) |
| AU (1) | AU2006210460B2 (enExample) |
| BR (1) | BRPI0607450A2 (enExample) |
| CA (1) | CA2597198C (enExample) |
| CR (1) | CR9332A (enExample) |
| IL (1) | IL184803A (enExample) |
| MX (1) | MX2007009403A (enExample) |
| NO (1) | NO20074474L (enExample) |
| RU (1) | RU2007133108A (enExample) |
| WO (1) | WO2006084226A2 (enExample) |
| ZA (1) | ZA200707275B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192698B1 (en) * | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
| US6927203B1 (en) * | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| KR101363252B1 (ko) * | 2005-02-04 | 2014-02-13 | 레이븐 바이오테크놀로지스, 인코퍼레이티드 | Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법 |
| WO2010080538A1 (en) | 2008-12-19 | 2010-07-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| CA2621502A1 (en) * | 2005-09-07 | 2007-03-15 | Medimmune, Inc. | Toxin conjugated eph receptor antibodies |
| ES2673822T3 (es) * | 2006-07-18 | 2018-06-25 | Sanofi | Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer |
| JP2010516259A (ja) | 2007-01-22 | 2010-05-20 | レイベン バイオテクノロジーズ | ヒトがん幹細胞 |
| CN101918844A (zh) * | 2007-06-18 | 2010-12-15 | 米迪缪尼有限公司 | 表达epha2和erbb2的细胞的协同治疗 |
| WO2009151717A2 (en) | 2008-04-02 | 2009-12-17 | Macrogenics, Inc. | Bcr-complex-specific antibodies and methods of using same |
| WO2009028639A1 (ja) | 2007-08-30 | 2009-03-05 | Daiichi Sankyo Company, Limited | 抗ｅｐｈａ２抗体 |
| WO2009085805A2 (en) * | 2007-12-21 | 2009-07-09 | Siemens Heathcare Diagnostics Inc. | Circulating epha2 receptor |
| JP5117917B2 (ja) | 2008-04-21 | 2013-01-16 | デクセリアルズ株式会社 | 保護素子及びその製造方法 |
| US8715654B2 (en) | 2008-10-02 | 2014-05-06 | Celtaxsys, Inc. | Methods of modulating the negative chemotaxis of immune cells |
| AR078470A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | Anticuerpos que se unen especificamente al receptor epha2 |
| DK2498796T3 (en) | 2009-11-09 | 2018-03-05 | Aal Scient Inc | HEART DISEASE TREATMENT |
| WO2011057251A2 (en) * | 2009-11-09 | 2011-05-12 | The Brigham And Women's Hospital, Inc. | Treatment of heart disease |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| PH12018501083A1 (en) | 2010-03-04 | 2019-02-18 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| RU2598711C2 (ru) * | 2010-07-22 | 2016-09-27 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Антитело к противоопухолевому антигену и способы применения |
| MX339622B (es) | 2010-08-02 | 2016-06-02 | Macrogenics Inc | Diacuerpos covalentes y sus usos. |
| EP2714079B2 (en) | 2011-05-21 | 2019-08-28 | MacroGenics, Inc. | Deimmunized serum-binding domains and their use for extending serum half-life |
| JP2015527869A (ja) | 2011-08-26 | 2015-09-24 | メリマック ファーマシューティカルズ インコーポレーティッド | タンデムＦｃ二重特異性抗体 |
| CA2850668A1 (en) * | 2011-10-04 | 2013-04-11 | Expression Pathology, Inc. | Srm/mrm assay for the ephrin type-a receptor 2 protein |
| JP5875054B2 (ja) * | 2013-02-13 | 2016-03-02 | 国立大学法人 東京大学 | がんの検査方法及び検査用キット |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| WO2014138449A1 (en) | 2013-03-06 | 2014-09-12 | Merrimack Pharmaceuticals, Inc. | Anti-c-met tandem fc bispecific antibodies |
| EP3152235B1 (en) | 2014-05-29 | 2021-08-25 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
| KR101636882B1 (ko) * | 2015-06-25 | 2016-07-06 | 전남대학교 산학협력단 | 인간 피브로넥틴 도메인 Ⅲ 기본 골격의 신규 인간 ＥｐｈＡ2 특이적 결합 단백질 및 그의 용도 |
| SMT202100527T1 (it) | 2015-07-30 | 2021-11-12 | Macrogenics Inc | Molecole di legame a pd-1 e lag-3 e loro metodi d'uso |
| SG11201804839WA (en) | 2015-12-14 | 2018-07-30 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
| US11534466B2 (en) | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
| EP3442574A4 (en) | 2016-04-15 | 2019-12-11 | MacroGenics, Inc. | Novel B7-H3 binding MOLECULES, ANTIBODY-ACTIVE CONJUGATES AND METHOD OF USE THEREOF |
| WO2018135653A1 (ja) * | 2017-01-23 | 2018-07-26 | 学校法人東洋大学 | 抗ｅｐｈａ２抗体及びこれを用いたｅｐｈａ２の免疫学的検出 |
| US11459394B2 (en) | 2017-02-24 | 2022-10-04 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
| SG11202005557TA (en) | 2017-12-12 | 2020-07-29 | Macrogenics Inc | Bispecific cd 16-binding molecules and their use in the treatment of disease |
| CN111787949A (zh) | 2018-02-15 | 2020-10-16 | 宏观基因有限公司 | 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途 |
| JP7326764B2 (ja) * | 2018-03-09 | 2023-08-16 | 東ソー株式会社 | 腫瘍マーカーならびに腫瘍細胞を夾雑細胞と区別して回収および検出する方法 |
| JP7745556B2 (ja) | 2020-02-21 | 2025-09-29 | マクロジェニクス，インコーポレーテッド | Ｃｄ１３７結合分子及びその使用 |
| AU2021289095A1 (en) * | 2020-06-12 | 2023-01-05 | Bicycletx Limited | Treatment of diseases characterized by overexpression of Erythropoietin-producing hepatocellular receptor A2 (EphA2) |
| KR102795760B1 (ko) | 2021-05-25 | 2025-04-15 | 주식회사 박셀바이오 | 모노바디 기반 키메라 항원 수용체 및 이를 포함하는 면역 세포 |
| KR20230140746A (ko) * | 2022-03-30 | 2023-10-10 | 연세대학교 산학협력단 | 암전이의 검출용 신규 바이오마커 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5824303A (en) | 1992-11-13 | 1998-10-20 | Amgen Inc. | Eck receptor ligands |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5532159A (en) | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| DK1141026T3 (da) | 1998-12-22 | 2007-03-26 | Raven Biotechnologies Inc | Sammensætninger og fremgangsmåder til frembringelse af monoklonale antistoffer repræsentative for en specifik celletype |
| CA2380888A1 (en) | 1999-08-17 | 2001-02-22 | Purdue Research Foundation | Treatment of metastatic disease |
| US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| JP4948728B2 (ja) | 1999-08-17 | 2012-06-06 | パーデュー・リサーチ・ファウンデーション | 癌診断用抗体 |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
| US6541225B1 (en) | 2000-01-26 | 2003-04-01 | Raven Biotechnologies, Inc. | Methods and compositions for generating human monoclonal antibodies |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| FR2838742B1 (fr) | 2002-04-23 | 2004-07-09 | Inst Nat Sante Rech Med | Epitopes t de l'antigene epha2 |
| WO2003094859A2 (en) * | 2002-05-10 | 2003-11-20 | Medimmune, Inc. | Epha2 monoclonal antibodies and methods of use thereof |
| EP1575509B1 (en) | 2002-05-10 | 2011-10-26 | Purdue Research Foundation | Epha2 agonistic monoclonal antibodies and methods of use thereof |
| KR101363252B1 (ko) * | 2005-02-04 | 2014-02-13 | 레이븐 바이오테크놀로지스, 인코퍼레이티드 | Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법 |
-
2006
- 2006-02-06 KR KR1020077019628A patent/KR101363252B1/ko not_active Expired - Fee Related
- 2006-02-06 ZA ZA200707275A patent/ZA200707275B/xx unknown
- 2006-02-06 AT AT06734397T patent/ATE551367T1/de active
- 2006-02-06 RU RU2007133108/13A patent/RU2007133108A/ru not_active Application Discontinuation
- 2006-02-06 CA CA2597198A patent/CA2597198C/en not_active Expired - Fee Related
- 2006-02-06 US US11/349,327 patent/US7569672B2/en not_active Expired - Fee Related
- 2006-02-06 AU AU2006210460A patent/AU2006210460B2/en not_active Ceased
- 2006-02-06 BR BRPI0607450-2A patent/BRPI0607450A2/pt not_active Application Discontinuation
- 2006-02-06 CN CN201410213409.1A patent/CN104059150B/zh not_active Expired - Fee Related
- 2006-02-06 JP JP2007554287A patent/JP5342145B2/ja not_active Expired - Fee Related
- 2006-02-06 CN CN200680011089.5A patent/CN101155830B/zh not_active Expired - Fee Related
- 2006-02-06 WO PCT/US2006/004057 patent/WO2006084226A2/en not_active Ceased
- 2006-02-06 MX MX2007009403A patent/MX2007009403A/es active IP Right Grant
- 2006-02-06 EP EP06734397A patent/EP1846450B1/en not_active Not-in-force
-
2007
- 2007-07-24 IL IL184803A patent/IL184803A/en not_active IP Right Cessation
- 2007-08-22 CR CR9332A patent/CR9332A/es not_active Application Discontinuation
- 2007-09-03 NO NO20074474A patent/NO20074474L/no not_active Application Discontinuation
-
2009
- 2009-06-30 US US12/495,218 patent/US7776328B2/en not_active Expired - Fee Related
- 2009-11-30 US US12/627,335 patent/US8183357B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1846450A4 (en) | 2008-05-28 |
| AU2006210460B2 (en) | 2012-04-05 |
| CA2597198C (en) | 2016-06-21 |
| WO2006084226A2 (en) | 2006-08-10 |
| EP1846450A2 (en) | 2007-10-24 |
| US7776328B2 (en) | 2010-08-17 |
| AU2006210460A1 (en) | 2006-08-10 |
| US20090263391A1 (en) | 2009-10-22 |
| HK1108163A1 (en) | 2008-05-02 |
| US20100086969A1 (en) | 2010-04-08 |
| WO2006084226A3 (en) | 2006-11-30 |
| NO20074474L (no) | 2007-11-05 |
| CN104059150A (zh) | 2014-09-24 |
| JP2008529497A (ja) | 2008-08-07 |
| ZA200707275B (en) | 2009-01-28 |
| US20060177453A1 (en) | 2006-08-10 |
| MX2007009403A (es) | 2007-10-02 |
| US8183357B2 (en) | 2012-05-22 |
| IL184803A0 (en) | 2007-12-03 |
| EP1846450B1 (en) | 2012-03-28 |
| US7569672B2 (en) | 2009-08-04 |
| CR9332A (es) | 2008-03-18 |
| KR20070107721A (ko) | 2007-11-07 |
| KR101363252B1 (ko) | 2014-02-13 |
| CA2597198A1 (en) | 2006-08-10 |
| RU2007133108A (ru) | 2009-03-10 |
| ATE551367T1 (de) | 2012-04-15 |
| CN104059150B (zh) | 2018-10-02 |
| CN101155830A (zh) | 2008-04-02 |
| BRPI0607450A2 (pt) | 2009-09-01 |
| CN101155830B (zh) | 2014-06-18 |
| JP5342145B2 (ja) | 2013-11-13 |
| AU2006210460A2 (en) | 2006-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL184803A (en) | Purified antibodies against epha2, methods for their production, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating cancer | |
| Vallera et al. | Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy | |
| Seon et al. | Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. | |
| Liu et al. | Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. | |
| JP3600617B2 (ja) | ヒト上皮細胞成長因子レセプターに特異的なモノクローナル抗体及びそれを用いた治療剤 | |
| US20230110128A1 (en) | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor | |
| JP3066983B2 (ja) | 膜結合ｃｄ３０抗原の蛋白質分解性開裂及び遊離を防ぐ抗ｃｄ３０抗体 | |
| CN117279932B (zh) | 依沙替康衍生物及其连接子-负载物和缀合物 | |
| US9249217B2 (en) | Bispecific EGFRvIII x CD3 antibody engaging molecules | |
| EP0742795A1 (en) | Immuno-stimulatory monoclonal antibodies | |
| TWI817190B (zh) | 抗ｃ-Ｍｅｔ抗體藥物偶聯物及其應用 | |
| WO2011137687A1 (zh) | 一种抗癌胚抗原抗体及其应用 | |
| AU2013271428B2 (en) | Human bispecific EGFRvIII antibody engaging molecules | |
| JPH06501705A (ja) | 抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療 | |
| WO2009132821A1 (en) | Interleukin (il-21) binding proteins and methods of making and using same | |
| CN109929037A (zh) | 针对程序性死亡配体的结合物及其应用 | |
| JP7545139B2 (ja) | Ｂ細胞急性リンパ芽球性白血病（ｂ－ａｌｌ）の処置のためのｃｄ２２標的化部分 | |
| WO1990011779A1 (en) | Heteroconjugates | |
| JPH115749A (ja) | 癌治療医薬品組成物 | |
| CN119215188B (zh) | 抗Trop2抗体和抗5T4抗体-自然杀伤细胞偶联物及其用途 | |
| CN112439060B (zh) | Pd-l1免疫疗法的新用途 | |
| AU2006200762B2 (en) | Compositions and methods for treatment of angiogenesis in pathological lesions | |
| AU650080B2 (en) | Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents | |
| Hohenstein | Immunotherapy: A novel treatment for non-Hodgkin's lymphoma | |
| ADAMS | A Human Tumor Xenograft Model of Therapy with a Bispecific Monoclonal Antibody Targeting c-erbu-2 and CD161 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |